Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neuroendocrine Tumors 1Gastric Cancer After D2 Lymph Node Dissection 1Gallbladder Neoplasms 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1

Interventions

Everolimus 6pasireotide 5Octreotide 5lanreotide 2ganitumab 2cabozantinib 2Bevacizumab 2surufatinib 1nintedanib 1ibrutinib 1gallium Ga 68 dotatate 1fosbretabulin 1epothilone B 1conatumumab 1cixutumumab 1carfilzomib 1azaspirane 1arginyllysine 1aflibercept 1Temozolomide 1TKM-080301 1Sunitinib 1Sorafenib 1Somatostatin 1Random Allocation 1Ramucirumab 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoid Tumor × Somatostatin × Clear all
NCT02795858 2025-02-19

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
43 enrolled 11 charts
Endocrine

Carcinoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡